Frameless Fractionated Stereotactic Radiation Therapy
RadiationOther names: FFSRT, Frameless SRT, FSRS
NCT Number: NCT02798029
This phase II trial studies the safety and efficacy of frameless fractionated stereotactic radiation therapy for brain metastases. Frameless fractionated stereotactic radiosurgery is a specialized radiation therapy that delivers 3 to 5, high dose fractions of radiation directly to the brain lesions while sparing normal tissues.
Looking for future studies?
Notify Me18 year and older
All sexes
Interventional
Phase 2
Presbyterian Hospital, Albuquerque, New Mexico, United States
PRIMARY OBJECTIVES:
I. To assess the efficacy and safety of frameless fractionated stereotactic radiation therapy (FFSRT) on the treatment of solitary and oligometastatic brain metastases in the MD Anderson Houston Area Locations, MD Anderson Radiation Treatment Centers in New Mexico, MD Anderson affiliates and the main campus of MD Anderson, for patients unable or unwilling to undergo frame-based stereotactic radiosurgery (SRS).
SECONDARY OBJECTIVES:
I. To assess 6-month local control, intracranial progression-free survival and overall survival.
II. To collect data on charges and reimbursements of patients treated with FFSRT to compare those charges and reimbursements if the same patients had been treated with single-fraction, frame-based gamma knife SRS.
OUTLINE:
Patients undergo FFSRT daily over 30 minutes for 3-5 days.
After completion of study treatment, patients are followed up every 3 months for up to 1 year.
Healthy volunteers accepted: No
Only the study team can determine whether someone qualifies for participation.
Inclusion criteria
Exclusion criteria
Other names: FFSRT, Frameless SRT, FSRS
Time frame: Up to 1 year
Time frame: Up to 1 year
Time frame: From enrollment to either the first observation of progression disease in the brain or death due to any cause, assessed up to 1 year
Will be summarized using the Kaplan-Meier method and the 50th percentile of the Kaplan-Meier distribution will determine the median intracranial PFS.
Time frame: Up to 1 year
Will be summarized using the Kaplan-Meier method and the 50th percentile of the Kaplan-Meier distribution will determine the median intracranial OS.
Time frame: Up to 1 year
Will be summarized using descriptive statistics such as mean, median, standard deviation, and range. Comparisons in cost between treatment modalities will be evaluated using a paired t-test where each patient will serve as his or her own control to determine if the cost of frameless fractionated stereotactic radiation therapy (FFSRT) is comparable to standard treatment.
M.D. Anderson Cancer Center
Other
A Phase II Study of the Efficacy, Safety, and Cost of Frameless Fractionated Stereotactic Radiation for Parenchymal Brain Metastases
OpenTrials presents study information sourced from ClinicalTrials.gov. The official registry record should be consulted for the latest information.
View the official ClinicalTrials.gov record (opens in a new tab)This listing is for discovery and informational purposes only. It is not medical advice, does not guarantee that a study is recruiting, and does not determine eligibility. Contact the study team and a qualified healthcare professional when considering participation.
Published trials that share one or more normalized conditions with this study.
NCT04895592
Brain Diseases, Brain Neoplasms
Atlanta, Georgia, United States
View Trial DetailsNCT03680144
Brain Diseases, Brain Neoplasms
Atlanta, Georgia, United States
View Trial DetailsNCT02595905
Brain Diseases, Brain Neoplasms
Anchorage, Alaska, United States
View Trial DetailsNCT02858869
Brain Diseases, Brain Neoplasms
Atlanta, Georgia, United States
View Trial Details